BetterLife Pharma (XCNQ:BETR) Growth Rank : 0 (As of Dec. 15, 2024)

View and export this data going back to 2017. Start your Free Trial

What is BetterLife Pharma Growth Rank?

BetterLife Pharma has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

BetterLife Pharma Growth Rank Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

BetterLife Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (XCNQ:BETR) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

BETRF:USA NPAU:Germany

Address

1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6

Website

https://www.abetterlifepharma.com

BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and the European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.

Executives